Trikafta 75 mg

TRIKAFTA 75 MG granules contain ivacaftor, a medication used to treat cystic fibrosis. This oral formulation is designed for patients who require a specific dosage form.

TRIKAFTA 75 MG granules are primarily used in the management of cystic fibrosis. Ivacaftor, the active ingredient, works to improve the function of a protein affected by this genetic condition. Patients may use this medication as part of a broader treatment plan to manage symptoms and improve respiratory function.

Common effects of TRIKAFTA 75 MG granules may include improvements in lung function and overall health for individuals with cystic fibrosis. Some users might experience gastrointestinal discomfort or other mild side effects. It is important to monitor for any adverse reactions and consult a healthcare provider if concerns arise.

TRIKAFTA 75 MG granules should be handled with care, ensuring proper storage and administration as directed. Patients should be aware of potential allergies to ivacaftor or any inactive ingredients. Regular medical check-ups are recommended to monitor the effectiveness and safety of the treatment.

TRIKAFTA 75 MG granules may interact with certain medications, including those metabolized by the liver's CYP3A enzymes. It is advisable to inform healthcare providers about all current medications to avoid potential interactions. Alcohol and other substances that affect liver function should be used with caution.